Perspectives actuelles sur l’intégration des médicaments biosimilaires à la pratique de l’oncologie au Canada

Nancy Nixon, Jennifer Newton, Pauline Hamilton

Abstract


Les biomédicaments sont de plus en plus utilisés pour traiter le cancer au Canada, mais les coûts élevés de développement et de fabrication représentent un fardeau économique considérable pour le système de santé (Godman et al., 2018; Cornes et al., 2012). Les médicaments biosimilaires ressemblent énormément aux biomédicaments originaux. Ils présentent les mêmes profils d’innocuité, d’efficacité et d’immunogénicité que les biomédicaments « de référence » (Barbier et al., 2019; European Medicines Agency, 2017), mais ils coûtent moins cher que leurs équivalents originaux, car ils s’appuient sur des essais cliniques existants, ce qui accélère le processus de développement et d’approbation. Cette réduction des coûts améliore l’accès aux biothérapies pour les patients et multiplie les options de traitement à la disposition des professionnels de la santé et des patients (Simon Kucher & Partners, 2016).


Full Text:

PDF

References


Afzali, A., Furtner, D., Melsheimer, R., & Molloy, P. (2021, March 21). The automatic substitution of biosimilars: Definitions of interchangeability are not interchangeable. Advances in Therapy, 38(5), 1–7. https://doi.org/10.1007/s12325-021-01688-9

Barbier, L., Declerck, P., Simoens, S., Neven, P., Vulto, A., & Huys, I. (2019, July 1). The arrival of biosimilar monoclonal antibodies in oncology: Clinical studies for trastuzumab biosimilars. British Journal of Cancer, 121(3), 199–210. https://doi.org/10.1038/s41416-019-0480-z

Barbier, L., Simoens, S., Vulto, A. G., & Huys, I. (2020, November 3). European stakeholder learnings regarding biosimilars: Part I - Improving biosimilar understanding and adoption. BioDrugs, 34, 783–796. https://doi.org/10.1007/s40259-020-00452-9

Cancer Care Ontario. (2021). Biosimilars – What you need to know—Pan-Canadian Oncology Biosimilars Initiative. https://www.cancercareontario.ca/en/guidelines-advice/modality/biological-therapy/biosimilars-need-to-know-providers

Cornes, P. (2012, January 17). The economic pressures for biosimilar drug use in cancer medicine. Target Oncol, S57–S67. https://doi.org/10.1007/s11523-011-0196-3

European Medicines Agency. (2017). Biosimilar medicines: Overview. https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview

European Specialist Nurses Organisation. (2019, May 9). Switch management between similar biological medicines: A communication and information guide for nurses. http://www.esno.org/assets/files/biosimilar-nurses-guideline-final_EN-lo.pdf

Generics and Biosimilar Initiative. (2014, January 31). Biosimilars approved in Canada. https://www.gabionline.net/biosimilars/general/biosimilars-approved-in-canada

Godman, B., Bucsics, A., Vella Bonanno, P., Oortwijn, W., Rothe, C., Ferrario, A., ... Haycox, A. (2018, December 5). Barriers for access to new medicines: Searching for the balance between rising costs and limited budgets. Frontiers in Public Health, 6(328). https://doi.org/10.3389/fpubh.2018.00328

Health Canada. (2019, August 27). Biosimilar biologic drugs in Canada: Fact Sheet. https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html

Ismailov, R., Pouillon, L., Selinger, C., & Khasanova, Z. D. (2021, November 1). Knowledge and awareness of biosimilars and shared decision-making among gastroenterology team members in Colorado, USA. Expert Opinion on Biological Therapy, 21(1), 111–119. https://doi.org/10.1080/14712598.2020.1842355

New Brunswick Canada – Health. (n.d.). Biosimilars Initiative. https://www2.gnb.ca/content/gnb/en/departments/health/MedicarePrescriptionDrugPlan/NBDrugPlan/biosimilars.html#:~:text=The%20New%20Brunswick%20Department%20of,by%20British%20Columbia%20and%20Alberta

Simon Kucher & Partners. (2016). Medicines for Europe - Payers’ price & market access policies supporting a sustainable biosimilar medicines market: Final Report. https://www.medicinesforeurope.com/wp-content/uploads/2016/09/Simon-Kucher-2016-Policy-requirements-for-a-sustainable-biosimilar-market-FINAL-report_for-publication2.pdf

Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A. G., & Huys, I. (2021, February). Informing patients about biosimilar medicines: The role of European patient associations. Pharmaceuticals, 14(2), 117. https://doi.org/10.3390/ph14020117


Refbacks

  • There are currently no refbacks.